Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -33,8 +33,77 @@
33	33
34	34	With a vision to enhance the quality benchmark of primary packaging material of pharmaceutical products, Square Pharmaceuticals produc[[image:bottle.jpg||alt="PET Bottle" height="113" style="float:right" width="72"]]e[[image:caps.jpg||alt="caps" height="76" style="float:right" width="84"]]s Pharma-grade PET bottle & caps using the single stage ‘SIPA’ branded Italian machinery. The company promotes the products of this division based on Class D production facility and the SIPA technology. Also, the company commits a ‘SQUARE’ quality for its customers, which primarily refers to the brand value of the company. Products of this division include Round Transparent PET Bottle, Oval Transparent PET Bottle, Round Amber PET Bottle of different variants such as 200ml, 100ml, 60ml, and 30ml. Also, the division produces Closure 28MM While Single and Double Unprint caps.
35	35
	36	+=== AgoVet Division ===
36	36
	38	+The AgroVet division of the company has started its operation in 1998 with only 3 locally manufactured products, which now stands at 73. The division manufactures, imports and markets poultry and livestock medicines successfully. It imports versatile products from overseas principles such as France, Holland, Germany, India, Thailand & China. The company has recently started marketing of the products of the biggest global veterinary pharmaceutical company – Schering Plough Animal Health. Also, the division has signed distribution agreements with renowned veterinary injectable manufacturers Norbrook Laboratories & DOW, USA.
37	37
	40	+The AgroVet division has a subdivision of repacking, marketing and selling pesticides, agricultural chemicals, and public health insecticides. The agrochemical products include fungicides, insecticides, herbicides, mosquito control aerosol and so on. The packaging and manufacturing facilities are populated with pneumatic controlled machineries, experienced personnel, and adaptable work environment to ensure safety.
38	38
	42	+=== API Unit ===
39	39
	44	+With an aim to reduce dependency on import for Active Pharmaceuticals Ingredients (API), Square Pharmaceuticals is manufacturing international standard API in Bangladesh. The facility is located in Pabna. The customers of this division of the company are the other pharmaceutical companies in the country. The company plans to further expand the business in both domestic and international market by capitalizing a project of the government – to establish Industrial Park to produce API. The Park will be established in Gazaria, Munshiganj holding 200 acres of land. The company has received highest allocated 3 plots to a single company in the API Industrial Park. Currently, Square produces the following APIs –
	45	+
	46	+* Amoxicillin Trihydrate BP (Compacted & Micronized)
	47	+* Cloxacillin Sodium BP (Compacted & Micronized)
	48	+* Flucloxacillin Sodium BP (Compacted & Micronized)
	49	+* Diclofenac Sodium BP
	50	+* Diclofenac INN Bulk (Free Acid)
	51	+* Diclofenac Potassium BP
	52	+* Diclofenac Diethylamine BP
	53	+* Paracetamol BP
	54	+
	55	+=== Herbal & Ayurvedic Site ===
	56	+
	57	+This line of production is being pursued by Square covering following Therapeutic classes in Herbal medicine –
	58	+
	59	+* Anti-tussive & Expectorant
	60	+* Hepato-protective
	61	+* CNS & antidepressant
	62	+* Cardiovascular
	63	+* Adaptogen & Immunomodulator
	64	+* Vitamin & mineral supplement
	65	+* Hematinic
	66	+* Gastrointestinal
	67	+* Topical analgesics
	68	+* Hormonal
	69	+
	70	+Traditional Ayurvedic medicines cover energy tonic, digestive health products, liquid vitamins and so on.
	71	+
	72	+=== Square Lifesciences Ltd. ===
	73	+
	74	+Square Lifesciences Ltd (SLL) is a subsidiary almost fully owned by the parent company Square Pharmaceuticals Ltd. This entity enjoys the ‘subsidiary’ status and will be located at Patikabari, Hemayetpur, Pabna, Bangladesh. The project is currently under construction and active processes to obtain regulatory permissions from Bangladesh Investment Development Authority (BIDA), Directorate General of Drug Administration (DGDA), and Department of Environment (DOE) are ongoing. The plant is expected to go for production by the beginning of 2022.
	75	+
	76	+(% style="text-align:center" %)
	77	+[[image:square_life_science.jpg||alt="square lifesciences limited animated view" height="309" width="900"]]
	78	+
	79	+== Sister concerns of Square ==
	80	+
	81	+Square Pharmaceuticals Ltd. are listed below –
	82	+
	83	+* Square Hospitals Ltd
	84	+* Square Toiletries Ltd
	85	+* Square Food & Beverage Ltd
	86	+* Square Informatix Limited
	87	+* Square Fashion Limited
	88	+* Maasranga Communications Ltd
	89	+* Mediacom Limited
	90	+* Sabazpur Tea Company Ltd
	91	+* Aegis Services Ltd
	92	+* Square College of Nursing
	93	+* Astras Limited
	94	+* Square Air Limited
	95	+* Square Texcom Limited
	96	+* Sqaure Textiles Ltd
	97	+* Square Yarns Ltd
	98	+
	99	+Among these sister concerns, Square Textiles Ltd is listed in the stock markets.
	100	+
	101	+= Business overview =
	102	+
	103	+Revenue of the company comes from the sale of its manufactured products. Gross revenue of the company at the end of financial year 2020, ending June 2020, was BDT 52.93 billion. The company has grown 18.68% year-on-year in terms of revenue during that year. The company earn BDT 12.96 billion profit after tax (PAT) during the same year, a 22.66% growth year on year. Net asset value (NAV) stood at 69.85 million, a 14.87% increase year on year. Earnings per share of the company has grown 22.66% and stood at BDT 15.35 during the same year. The company paid cash dividend of BDT 3.97 billion during FY20.
	104	+
	105	+The pharmaceuticals industry is the least affected industry during Covid-19 pandemic restrictions in Bangladesh. According to the annual report 2020 of Square Pharmaceuticals, the company has faced fewer restrictions, no disruption in raw materials supply, or any delay in production and distribution. Therefore, the company has posted stellar performance figures in the last financial year. This indicates strong foothold of the company’s operation.
	106	+
	107	+
	108	+
40	40	{{putFootnotes/}}